News Headlines Article

Stalled Health Care Bill Leaves Drug Makers in Regulatory Limbo
New York Times - Duff Wilson

With the possible demise of health care legislation, getting back to business as usual may not be the best thing for the nation’s drug makers. After all, in return for the prospect of tens of millions of newly insured customers and a large degree of regulatory certainty, the pharmaceutical industry had agreed to pay a relatively small price: $8 billion a year in discounts and fees. It was a modest compromise for an industry with $246 billion in prescription drug sales last year.

Commands